title: Homeopathic mistletoe adverse reaction mimics nodal involvement in18F-FDG PET/CT performed for evaluation of response to chemotherapy in lymphoma.
abstract: Some patients use complementary medicine. We present a patient with Hodgkin's lymphoma, scanned with18F-FDG PET/CT for evaluation of response after chemotherapy, who was self-administering mistletoe as a homeopathic medicine product. The careful review of the images of the entire scan and patient collaboration in anamnesis were crucial to avoid a false positive result. A review of the published scientific data on the effects of mistletoe is also presented.
authors.affiliation: Servicio de Medicina Nuclear, Hospital Universitario Dr. Peset, Valencia, Spain. Electronic address: abreu_ped@hotmail.com.
authors.forename: P
authors.initials: P
authors.lastname: Abreu
authors.affiliation: Servicio de Medicina Nuclear y PET/TC, Hospital 9 de Octubre, Valencia, Spain.
authors.forename: R
authors.initials: R
authors.lastname: Sánchez
authors.affiliation: Servicio de Medicina Nuclear, Hospital Universitario Dr. Peset, Valencia, Spain.
authors.forename: T
authors.initials: T
authors.lastname: Mut
authors.affiliation: Servicio de Medicina Nuclear, Hospital Universitario Dr. Peset, Valencia, Spain.
authors.forename: D
authors.initials: D
authors.lastname: Balaguer
authors.affiliation: Servicio de Medicina Nuclear, Hospital Universitario Dr. Peset, Valencia, Spain.
authors.forename: I
authors.initials: I
authors.lastname: Latorre
authors.affiliation: Servicio de Medicina Nuclear, Hospital Universitario Dr. Peset, Valencia, Spain.
authors.forename: H
authors.initials: H
authors.lastname: Rodríguez
mesh_terms: D000328:Adult; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D001761:Bleomycin / Q000008:administration & dosage; D003606:Dacarbazine / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005462:Fluorine Radioisotopes / Q000032:analysis*; D019788:Fluorodeoxyglucose F18 / Q000032:analysis*; D006689:Hodgkin Disease / Q000000981:diagnostic imaging* / Q000188:drug therapy; D006801:Humans; D007279:Injections, Subcutaneous; D008198:Lymph Nodes / Q000000981:diagnostic imaging* / Q000187:drug effects; D008419:Materia Medica / Q000009:adverse effects*; D009367:Neoplasm Staging; D008517:Phytotherapy / Q000009:adverse effects*; D000072078:Positron Emission Tomography Computed Tomography; D019275:Radiopharmaceuticals / Q000032:analysis*; D054790:Ribosome Inactivating Proteins, Type 2 / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D012651:Self Medication; D050151:Subcutaneous Fat / Q000000981:diagnostic imaging / Q000378:metabolism; D014118:Toxins, Biological / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D014747:Vinblastine / Q000008:administration & dosage; D028182:Viscum album / Q000009:adverse effects*
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D005462:Fluorine Radioisotopes; D008419:Materia Medica; D019275:Radiopharmaceuticals; D054790:Ribosome Inactivating Proteins, Type 2; D014118:Toxins, Biological; C488862:mistletoe lectin I; D019788:Fluorodeoxyglucose F18; D001761:Bleomycin; D014747:Vinblastine; D003606:Dacarbazine; D004317:Doxorubicin; C000615276:Fluorine-18
keywords: (18)F-FDG; Evaluación de respuesta; Evaluation of response; Homeopathy; Homeopatía; Linfoma; Lymphoma; PET/CT; PET/TC